Persistent diarrhea with petechial rash - unusual pattern of light chain amyloidosis deposition on skin and gastrointestinal biopsies: A case report

Shawna E Bilton, Nikhil Shah, Diana Dougherty, Sarah Simpson, Alex Holliday, Farhad Sahebjam, Douglas J Grider

Abstract

BACKGROUND
Amyloidosis is a rare disease characterized by extracellular deposition of misfolded protein aggregated into insoluble fibrils. Gastrointestinal involvement in systemic amyloidosis is common, but is often subclinical or presents as vague and nonspecific symptoms. It is rare for gastrointestinal symptoms to be the main presenting symptom in patients with systemic amyloidosis, causing it to be undiagnosed until late-stage disease.

CASE SUMMARY
A 53 year-old man with diarrhea, hematochezia, and weight loss presented to a community hospital. Colonoscopy with biopsy at that time was suspicious for Crohn disease. Due to worsening symptoms including nausea, vomiting, and a new petechial rash, an abdominal fat pad biopsy was done. The biopsy showed papillary and adnexal dermal amyloid deposition, in a pattern usually seen with cutaneous amyloidosis. However, Cytokeratin 5/6 was negative, excluding cutaneous amyloidosis. The patterns of nodular amyloidosis, subcutaneous
Amyloid deposits and perivascular amyloid were not seen. Periodic Acid-Schiff stain was negative for lipoid proteinosis, Congo red was positive for apple green birefringence on polarization and amyloid typing confirmed amyloid light chain amyloidosis. Repeat endoscopic biopsies of the gastrointestinal tract showed amyloid deposition from the esophagus to the rectum, in a pattern usually seen in serum amyloid A in the setting of chronic inflammatory diseases, including severe inflammatory bowel disease. Bone marrow biopsy showed kappa-restricted plasma cell neoplasm.

**CONCLUSION**

Described is an unusual presentation of primary systemic amyloidosis, highlighting the risk of misdiagnosis with subsequent significant organ dysfunction and high mortality.

**Core Tip:** Gastrointestinal involvement in systemic amyloid light (AL) amyloidosis is rare, and symptoms are usually subclinical. Diarrhea and hematochezia have rarely been the primary presenting symptom of AL amyloidosis. It is critically important to diagnose and treat amyloidosis early to prevent severe morbidity and mortality.

**Citation:** Bilton SE, Shah N, Dougherty D, Simpson S, Holliday A, Sahebjam F, Grider DJ. Persistent diarrhea with petechial rash - unusual pattern of light chain amyloidosis deposition on skin and gastrointestinal biopsies: A case report. *World J Clin Cases* 2022; 10(28): 10252-10259

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i28/10252.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i28.10252

**INTRODUCTION**

Amyloidosis is a rare disease characterized by extracellular deposition of misfolded protein aggregated into insoluble fibrils[1]. Arranged in an anti-parallel, cross-β-pleated sheet configuration, these fibrils are resistant to proteolytic cleavage and have specific tropism for tissue sites such as the heart, liver, kidney, and peripheral nervous system[2]. Amyloidosis is classified by the fibril precursor protein[3]. Six types of amyloidosis are generally recognized: primary (associated with monoclonal light chains in serum and/or urine), secondary (associated with inflammatory, infectious, and neoplastic diseases), hemodialysis-related, hereditary, senile, and localized[4]. Amyloid light (AL) (primary) amyloidosis is the most common systemic subtype of amyloidosis[5]. Caused by an underlying plasma cell dyscrasia, AL amyloidosis is characterized by deposition of soluble immunoglobin free lambda and kappa light chains as insoluble amyloid fibrils in tissues, resulting in a disruption of tissue structure and function[3]. Concurrent diagnosis of AL amyloidosis with multiple myeloma has been reported in 10%-15% of patients[2].

Early clinical features of AL amyloidosis are often vague and nonspecific, such as weight loss and fatigue, leading to delayed diagnosis and treatment[6]. Approximately 30% of patients with AL amyloidosis are diagnosed with advanced, late stage disease presenting with symptoms of end-stage organ damage with survival of only 3-6 mo[7]. The degree of cardiac involvement is the critical prognostic factor for patients with AL amyloidosis[8]. Cardiac involvement is common in amyloidosis, affecting 75%-80% of patients at diagnosis and is evident by elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) and visualization on echocardiography[8,9]. Renal involvement is found in 60%-75% of patients with AL amyloidosis, manifested as nephrotic range proteinuria and progressing to end stage renal disease[8]. Gastrointestinal involvement in amyloidosis with biopsy-proven disease is rare, as evident by a single center, 13-year retrospective study where 3.2% of patients with amyloidosis had biopsy-confirmed gastrointestinal amyloid involvement[10]. However, gastrointestinal amyloid involvement and symptoms are relatively common but often are subclinical and not typically the presenting symptom[3]. Reported symptoms of gastrointestinal amyloidosis include nausea, constipation, abdominal pain, reflux, weight loss, and gastrointestinal bleeding[10]. When amyloid deposition diffusely involves the tubular gastrointestinal tract, serum amyloid A should be considered, especially in the setting of chronic inflammatory conditions or autoimmune diseases[11]. By comparison, biopsies in the setting of AL amyloidosis can have nodular amyloid deposition rather than diffuse deposition involving the entire tubular gastrointestinal tract.
If amyloidosis is suspected, biopsy with histological confirmation is standard, usually an abdominal fat pad or rectal biopsy. Congo red staining of amyloid containing tissues results in the characteristic apple-green birefringence when viewed under polarized light[12]. Confirmation of amyloid type is done by mass spectrometry.

CASE PRESENTATION

Chief complaints
A 53-year-old man with a largely unremarkable past medical history was hospitalized with worsening diarrhea, hematochezia, weight loss, abdominal pain, and petechial rash of the trunk, arms, neck, and face including eyelids (Figure 1). The patient reported 6 mo of chronic diarrhea with intermittent hematochezia and an associated 13.5-18 kg weight loss.

History of present illness
Two weeks prior to his presentation at our institution, the patient presented to an outside community hospital’s emergency department with the above symptoms. At this community hospital, the patient underwent colonoscopy to the proximal colon with three biopsies by a general surgeon. Colonoscopy showed edematous, friable mucosa from the rectum to cecum. The pathology report noted acute and chronic inflammation with preserved glandular architecture, suspicious for Crohn disease. The patient was discharged from this outside hospital in stable condition and scheduled follow-up for presumed Crohn disease. Due to worsening symptoms of nausea, vomiting, diarrhea, dyspnea, and rash, he presented to the emergency department at our institution.

Physical examination
On initial examination, he was ill-appearing with a diffusely tender abdomen and a new petechial rash over the face and areas of pressure on his neck, arms, and abdomen. His lungs were clear to auscultation bilaterally without wheezing. His heart was in regular rhythm with increased rate and without murmur. In the emergency department, his vitals showed he was hypotensive, tachycardic, afebrile, and non-hypoxic on room air. His blood pressure dropped to 87/50 mmHg requiring intravenous (IV) fluid resuscitation, but did not require vasopressors.

Laboratory examinations
Initial labs revealed anemia (Hgb 9.1 g/dL, Hct 27.9%, RDW 15.4%, MCV 80.9 fl) and platelet count within normal limits at 233 k/μL. Chemistry panel showed acute kidney injury with Cr 1.57 mg/dL as well as low calcium of Ca 7.7mg/dL, elevated BUN of 21 mg/dL, and low albumin of 1.9 g/dL. C-reactive protein within normal limits at 0.80 mg/dL. Labs showed high stool lactoferrin of 332.15 μg/mL (normal range 0-7.24 μg/mL) and high pro-BNP of 10212 pg/mL (normal range < 125 pg/mL). Folate and thiamine labs were low. Urinalysis was remarkable for proteinuria of 100 mg/dL and the presence of numerous hyaline casts and coarse granular casts.

Imaging examinations
Imaging studies were performed including computer tomography (CT) chest, abdomen and pelvis with IV contrast. CT chest showed a moderate pericardial effusion and trace pleural effusions. CT abdomen/pelvis showed moderate wall thickening of the small bowel loops and colon extending from the cecum to the transverse colon (Figure 2), concerning for enterocolitis of infectious vs inflammatory etiology. No bone fractures or suspicious osseous abnormalities seen on any imaging. Echocardiogram showed normal left ventricular ejection fraction and small to moderate sized circumferential pericardial effusion without evidence of tamponade.

Further diagnostic work-up
The initial multidisciplinary work up was based on the suspected diagnosis of Crohn disease. Upon dermatology evaluation of a petechial skin rash, a fat pad biopsy was performed (Figure 3) to rule out possible amyloidosis or the unlikely possibility of metastatic cutaneous Crohn disease. Gastroenterology performed esophagogastroduodenoscopy and colonoscopy with biopsies from the esophagus, stomach, duodenum, terminal ileum, and colon (Figures 4 and 5). Both the fat pad biopsy and all biopsies from the gastrointestinal tract showed pink amorphous material. Interestingly, the pink amorphous material in the abdominal fat pad biopsy was only found just below the epidermis in the papillary dermis and in the upper perianal dermis of pilosebaceous units (Figure 3). This pattern of amyloid deposition is typically seen in primary cutaneous amyloidosis of macular or lichen subtype, or rarely in lipid proteinosis[13,14]. Cytokeratin 5/6 was only blush positive and thus interpreted as negative, helping to exclude macular or lichen amyloidosis. Periodic Acid-Schiff with and without digestion was negative for lipid proteinosis, which can also have perivascular dermal and mucosal deposits of eosinophil amorphous material.
Figure 1  Petechial rash on patient’s abdomen, neck, and face, most prominent in areas of friction.

Figure 2  Computed tomography abdomen and pelvis with intravenous contrast with moderate wall thickening of the small bowel loops and colon extending from the cecum to the transverse colon.

Ongoing work up further revealed the following: elevated immunoglobulin G (3412 mg/dL; normal range 600-1640), low immunoglobulin A (33 mg/dL; normal range 47-310) quantitative kappa and quantitative lambda of 1090 mg/dL and 22 mg/dL, respectively, with a kappa/lambda ratio of 49.55 (normal range 1.29-2.55). Serum protein electrophoresis showed a restricted band (M-spike) migrating in the gamma globulin region; subsequent immunofixation showed an IgG kappa monoclonal gammapathy with an additional abnormal kappa free light chain present. No abnormal peaks were found on urine protein electrophoresis, although 24-h urine protein was elevated at 745 mg/d. The patient underwent a left iliac bone marrow biopsy for evaluation, which identified a kappa-restricted plasma cell neoplasm, constituting 30%-40% of cellularity, and negative for amyloid. Plasma cell FISH detected duplication of chromosome 1q and gain of chromosomes 5, 9, 15. Peripheral blood smear identified early rouleaux formation.

FINAL DIAGNOSIS

Correlation of the biopsies to the patient’s clinical presentation was crucial to accurate diagnosis of systemic amyloidosis. When stained with Congo red stain, all skin and gastrointestinal biopsies showed
The pink amorphous material to be apple green birefringent under polarized light. A diagnosis of amyloidosis was made, and amyloid typing by mass spectrometry confirmed kappa light chain type amyloidosis.

TREATMENT

Due to hypotension on initial evaluation in the emergency department, he received IV fluid and was admitted to the intensive care unit (ICU). Given our differential included sepsis, he was started on empiric antibiotics, which were discontinued after negative blood cultures and stabilization of blood pressure. He received midodrine for symptomatic orthostatic hypotension. Hemoglobin dropped to 6.7 g/dL, requiring multiple blood product transfusions throughout admission to maintain hemoglobin goal of 7 mg/dL. He received electrolyte, folate, and thiamine supplementation during admission. He was scheduled for outpatient follow up with hematology and oncology for initiation of amyloidosis treatment.

OUTCOME AND FOLLOW-UP

The patient was stabilized and discharged home, however, he returned to the emergency department soon after with worsening shortness of breath, nausea, vomiting, diarrhea and fatigue. The patient was found to be hypotensive to 83/53 mmHg and was admitted to ICU with work up and treatment for bacteremia and septic shock. He was started on treatment for systemic amyloidosis with cyclophosphamide, bortezomib and dexamethasone. He was stabilized, discharged, and continued treatment for amyloidosis outpatient.

DISCUSSION

Reported is a patient presenting with diarrhea, hematochezia, weight loss, nausea and new onset...
Figure 4 Esophagastroduodenoscopy and colonoscopy images. A-C: Esophagastroduodenoscopy shows petechial lesions and friable mucosa scattered throughout distal esophagus to duodenum; D-I: Colonoscopy images show petechial lesions and shallow ulcers in colon.

Figure 5 Histopathology from colon biopsy. A: H&E stain at 4 × of colon biopsy shows fragments of colonic mucosa with amorphous homogenized pink material; B: Congo red stained colon tissue at 4 × shows the classic salmon-color; C: Congo red stain colon tissue at 4 × under polarization shows apple green birefringence.

petechial rash, with an initial diagnosis of Crohn disease based on a colonoscopy at a community hospital. The patient’s worsening symptoms prompted presentation to our institution’s emergency department with admission and further work up. A diagnosis of AL amyloidosis was made after the patient presented in hypotensive shock and underwent fat pad biopsy with amyloid staining. An underlying plasma cell neoplasm was confirmed with bone marrow biopsy.

Gastrointestinal involvement in systemic amyloidosis is common, but is often subclinical or presenting as vague and nonspecific symptoms[3]. It is rare for gastrointestinal symptoms to be the main presenting symptom in patients with systemic amyloidosis, causing it to be undiagnosed until late-stage disease[3,15]. Gastrointestinal involvement in amyloidosis is defined as the presence of
gastrointestinal symptoms with biopsy verification of amyloid. In gastrointestinal amyloidosis, clinical presentation could include abdominal pain, nausea, weight loss, malabsorption, and bleeding[16].

Upon extensive chart review, seven months prior the patient presented to an outpatient family practice clinic with new onset diarrhea and a few episodes of intermittent scant hematochezia. He denied dyspnea, weight loss, fatigue, or rash at that time. At that time, the differential diagnosis included hemorrhoids, diverticulosis, or malignancy. Vital signs were stable, complete blood count showed Hgb 13.6 g/dL (reference range 13.0-16.0 g/dL) and caseinomacropeptide within normal limits with the exception of elevated total protein at 8.6 (reference range 6.0-8.3 g/dL). He was referred for a colonoscopy which was not completed at that time. This appears to be the first presentation of the patient’s underlying amyloidosis, and his symptoms progressively worsened after this initial office visit. Consistent with other reports in the literature, the diagnosis of AL amyloidosis in this patient was made after presentation with advanced, late stage disease with multi-organ system involvement. Interestingly to this case, worsening gastrointestinal symptoms and a new petechial rash were the primary symptoms of AL amyloidosis that motivated reconsideration of the initial diagnostic impression of Crohn disease.

A multidisciplinary approach culminated in a fat pad biopsy to secure the diagnosis of systemic AL amyloidosis as the etiology of the patient’s gastrointestinal symptoms.

Endoscopy findings of amyloidosis have been reported as erythema, erosions, ulcerations, friability, polypoid protrusions and submucosal hematomas[17]. If AL amyloid deposition is within blood vessels vessel wall fragility, manifests as “pinch purpura” in cutaneous amyloidosis or as erythema with friability and focal hemorrhage in the tubular gastrointestinal tract. Previous studies have found endoscopic findings such as submucosal hematomas to be highly suggestive of AL amyloidosis, requiring biopsy and Congo red staining to confirm[17]. When amyloid is deposited as a nodule or mass-like lesion, these symptoms are usually not seen. This can also be a pattern of deposition in AL amyloidosis.

**CONCLUSION**

Prevalence of AL amyloidosis is increasing, with a rise from 15.5 to 40 cases per million over a 9-year period[5] underscoring the importance of early recognition and treatment. For patients with persistent gastrointestinal symptoms, weight loss, evidence of malabsorption and nonspecific endoscopic findings, a diagnosis of amyloidosis should be considered and biopsy with Congo red staining performed. It is critically important to diagnose and treat amyloidosis early to prevent severe morbidity, as in this case, and mortality.

**FOOTNOTES**

**Author contributions:** Bilton SE and Shah N reviewed the literature and contributed to the manuscript drafting; Sahebjam F and Dougherty D performed gastroenterology consultation; Sahebjam F performed endoscopy with biopsy; Simpson S and Holliday A performed dermatology consultation and skin biopsy; Grider DJ performed pathology consultation, pathology interpretation, reviewed literature, and contributed to manuscript drafting; all authors reviewed the manuscript, provided edits, and issued final approval for the version to be submitted.

**Informed consent statement:** A written informed consent was obtained from the patient for publication of this case report.

**Conflict-of-interest statement:** The authors declare they have no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** United States

**ORCID number:** Shawna E Bilton 0000-0003-2282-6754; Douglas J Grider 0000-0002-6346-094X.

**S-Editor:** Wang DM

**L-Editor:** A

**P-Editor:** Wang DM
REFERENCES

1 Hazenberg BP. Amyloidosis: a clinical overview. *Rheum Dis Clin North Am* 2013; 39: 323-345 [PMID: 23597967 DOI: 10.1016/j.rdc.2013.02.012]

2 Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. *N Engl J Med* 2003; 349: 583-596 [PMID: 12904524 DOI: 10.1056/NEJMra023144]

3 Sattianayagam PT, Hawkins PN, Gillmore JD. Systemic amyloidosis and the gastrointestinal tract. *Nat Rev Gastroenterol Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]

4 Alshehri SA, Hussein MRA. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint. *Gastroenterology Res Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]

5 Alshehri SA, Hussein MRA. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint. *Gastroenterology Res Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]

6 Alshehri SA, Hussein MRA. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint. *Gastroenterology Res Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]

7 Alshehri SA, Hussein MRA. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint. *Gastroenterology Res Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]

8 Alshehri SA, Hussein MRA. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint. *Gastroenterology Res Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]

9 Alshehri SA, Hussein MRA. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint. *Gastroenterology Res Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]

10 Alshehri SA, Hussein MRA. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint. *Gastroenterology Res Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]

11 Alshehri SA, Hussein MRA. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint. *Gastroenterology Res Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]

12 Alshehri SA, Hussein MRA. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint. *Gastroenterology Res Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]

13 Alshehri SA, Hussein MRA. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint. *Gastroenterology Res Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]

14 Alshehri SA, Hussein MRA. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint. *Gastroenterology Res Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]

15 Alshehri SA, Hussein MRA. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint. *Gastroenterology Res Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]

16 Alshehri SA, Hussein MRA. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint. *Gastroenterology Res Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]

17 Alshehri SA, Hussein MRA. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint. *Gastroenterology Res Hepatol* 2009; 6: 608-617 [PMID: 19724253 DOI: 10.1038/nrgastro.2009.147]
